294 related articles for article (PubMed ID: 22100163)
1. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis.
Napier RJ; Rafi W; Cheruvu M; Powell KR; Zaunbrecher MA; Bornmann W; Salgame P; Shinnick TM; Kalman D
Cell Host Microbe; 2011 Nov; 10(5):475-85. PubMed ID: 22100163
[TBL] [Abstract][Full Text] [Related]
2. The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas.
Cleverley TL; Peddineni S; Guarner J; Cingolani F; Garcia PK; Koehler H; Mocarski ES; Kalman D
PLoS Pathog; 2023 May; 19(5):e1011387. PubMed ID: 37200402
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
Tipping AJ; Baluch S; Barnes DJ; Veach DR; Clarkson BM; Bornmann WG; Mahon FX; Goldman JM; Melo JV
Leukemia; 2004 Aug; 18(8):1352-6. PubMed ID: 15201856
[TBL] [Abstract][Full Text] [Related]
4. Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages.
Bruns H; Stegelmann F; Fabri M; Döhner K; van Zandbergen G; Wagner M; Skinner M; Modlin RL; Stenger S
J Immunol; 2012 Oct; 189(8):4069-78. PubMed ID: 22988030
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells.
Kirschner KM; Baltensperger K
Mol Cancer Res; 2003 Nov; 1(13):970-80. PubMed ID: 14638869
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.
Nimmanapalli R; Bhalla K
Curr Opin Oncol; 2002 Nov; 14(6):616-20. PubMed ID: 12409651
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.
La Rosée P; Johnson K; Corbin AS; Stoffregen EP; Moseson EM; Willis S; Mauro MM; Melo JV; Deininger MW; Druker BJ
Blood; 2004 Jan; 103(1):208-15. PubMed ID: 12933582
[TBL] [Abstract][Full Text] [Related]
9. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
Wong S; McLaughlin J; Cheng D; Zhang C; Shokat KM; Witte ON
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17456-61. PubMed ID: 15505216
[TBL] [Abstract][Full Text] [Related]
10. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
12. A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment.
von Bubnoff N; Barwisch S; Speicher MR; Peschel C; Duyster J
Cell Cycle; 2005 Mar; 4(3):400-6. PubMed ID: 15738656
[TBL] [Abstract][Full Text] [Related]
13. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
Growney JD; Clark JJ; Adelsperger J; Stone R; Fabbro D; Griffin JD; Gilliland DG
Blood; 2005 Jul; 106(2):721-4. PubMed ID: 15790786
[TBL] [Abstract][Full Text] [Related]
14. Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl.
Gu JJ; Santiago L; Mitchell BS
Blood; 2005 Apr; 105(8):3270-7. PubMed ID: 15604220
[TBL] [Abstract][Full Text] [Related]
15. Sclerotiorin inhibits protein kinase G from Mycobacterium tuberculosis and impairs mycobacterial growth in macrophages.
Chen D; Ma S; He L; Yuan P; She Z; Lu Y
Tuberculosis (Edinb); 2017 Mar; 103():37-43. PubMed ID: 28237032
[TBL] [Abstract][Full Text] [Related]
16. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
17. ARG tyrosine kinase activity is inhibited by STI571.
Okuda K; Weisberg E; Gilliland DG; Griffin JD
Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
[TBL] [Abstract][Full Text] [Related]
18. Acceleration of tumor growth and peri-tumoral blood clotting by imatinib mesylate (Gleevec).
Samoszuk M; Corwin MA
Int J Cancer; 2003 Sep; 106(5):647-52. PubMed ID: 12866022
[TBL] [Abstract][Full Text] [Related]
19. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.
Warmuth M; Simon N; Mitina O; Mathes R; Fabbro D; Manley PW; Buchdunger E; Forster K; Moarefi I; Hallek M
Blood; 2003 Jan; 101(2):664-72. PubMed ID: 12393636
[TBL] [Abstract][Full Text] [Related]
20. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ
J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
